Showing results (141-150 of 152) with videos related to
Sort By:
Pageof 16
The Lancet. Rheumatology|August 25, 2020
COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational studyJixin Zhong, Guifen Shen, Huiqin Yang, et al.Human Vaccines & Immunotherapeutics|March 19, 2026
Standardized neutralizing antibody assay for Coxsackievirus A10 in clinical trial: A framework for multivalent hand, foot, and mouth disease vaccine evaluationQian Wang, Lu Li, Junying Gao, et al.Journal of Medicinal Chemistry|March 31, 2012
Structure-guided design, synthesis, and evaluation of guanine-derived inhibitors of the eIF4E mRNA-cap interactionXiaoqi Chen, David J Kopecky, Jeff Mihalic, et al.Human Vaccines & Immunotherapeutics|June 17, 2022
Clinical evaluation of the lot-to-lot consistency of an enterovirus 71 vaccine in a commercial-scale phase IV clinical trialJinhua Chen, Pengfei Jin, Xiaoqi Chen, et al.Bioorganic & Medicinal Chemistry Letters|July 22, 2014
Optimization beyond AMG 232: discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein-protein interactionYingcai Wang, Jiang Zhu, Jiwen Jim Liu, et al.Vaccines|June 24, 2022
Immunogenicity and Safety of an Inactivated Enterovirus 71 Vaccine Administered Simultaneously with Hepatitis B Virus Vaccine, Group A Meningococcal Polysaccharide Vaccine, Measles-Rubella Combined Vaccine and Japanese Encephalitis Vaccine: A Multi-Center, Randomized, Controlled Clinical Trial in ChinaXiaodong Liu, Shaoying Chang, Ruize Wang, et al.Science Advances|December 15, 2015
A single iron site confined in a graphene matrix for the catalytic oxidation of benzene at room temperatureDehui Deng, Xiaoqi Chen, Liang Yu, et al.Medcomm|April 6, 2021
COVID-19 infection in patients with connective tissue disease: A multicity study in Hubei province, ChinaCong Ye, Jixin Zhong, Shaozhe Cai, et al.Bioorganic & Medicinal Chemistry Letters|December 7, 2007
Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonistsAn-Rong Li, Michael G Johnson, Jiwen Liu, et al.Eclinicalmedicine|August 4, 2022
Immunogenicity and safety of an enterovirus 71 vaccine in children aged 36-71 months: A double-blind, randomised, similar vaccine-controlled, non-inferiority phase III trialYeqing Tong, Xinyue Zhang, Jinhua Chen, et al.Pageof 16